240 related articles for article (PubMed ID: 36466989)
1. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis.
Tseng CH; Chen TH; Wu JL; Lee TY; Borghi JA; Lin JT; Nguyen MH; Hsu YC
JHEP Rep; 2023 Jan; 5(1):100617. PubMed ID: 36466989
[TBL] [Abstract][Full Text] [Related]
2. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.
Lai CL; Wong DK; Wong GT; Seto WK; Fung J; Yuen MF
JHEP Rep; 2020 Jun; 2(3):100112. PubMed ID: 32462119
[TBL] [Abstract][Full Text] [Related]
3. Current Trend in Antiviral Therapy for Chronic Hepatitis B.
Chien RN; Liaw YF
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216027
[TBL] [Abstract][Full Text] [Related]
4. A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study.
Peng CW; Jeng WJ; Yang HI; Liu YC; Chien RN; Liaw YF
J Gastroenterol Hepatol; 2022 Nov; 37(11):2164-2172. PubMed ID: 35869752
[TBL] [Abstract][Full Text] [Related]
5. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F; Stein K; Heyne R; Petersen J; Buggisch P; Berg C; Zeuzem S; Stallmach A; Sprinzl M; Schott E; Pathil-Warth A; von Arnim U; Keitel V; Lohmeyer J; Simon KG; Trautwein C; Trein A; Hüppe D; Cornberg M; Lammert F; Ingiliz P; Zachoval R; Hinrichsen H; Zipprich A; Klinker H; Schulze Zur Wiesch J; Schmiedeknecht A; Brosteanu O; Berg T
J Hepatol; 2023 May; 78(5):926-936. PubMed ID: 37062574
[TBL] [Abstract][Full Text] [Related]
6. Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B.
Azhari H; Frolkis AD; Shaheen AA; Israelson H; Pinto J; Congly SE; Borman MA; Aspinall AA; Stinton LM; Nguyen HH; Swain MG; Burak KW; Lee SS; Sadler MD; Coffin CS
Can Liver J; 2022 Nov; 5(4):453-465. PubMed ID: 38144400
[No Abstract] [Full Text] [Related]
7. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation".
Liaw YF; Chien RN
Kaohsiung J Med Sci; 2022 Apr; 38(4):295-301. PubMed ID: 35262284
[TBL] [Abstract][Full Text] [Related]
8. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis.
Geng J; Bao H; Chen Y; Shi L; Geng J; Wang Q; Yu H
Expert Rev Anti Infect Ther; 2020 Aug; 18(8):823-834. PubMed ID: 32329638
[TBL] [Abstract][Full Text] [Related]
9. Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population-based cohort study.
Hsu YC; Lin YH; Lee TY; Nguyen MH; Tseng CH; Ho HJ; Kao FY; Lin JT; Wu CY; Wu CY
Aliment Pharmacol Ther; 2023 Aug; 58(4):463-473. PubMed ID: 37341016
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis Flares Are Associated With Better Outcomes Than No Flare in Patients With Decompensated Cirrhosis and Chronic Hepatitis B Virus Infection.
Chang ML; Cheng JS; Chien RN; Liaw YF
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2064-2072.e2. PubMed ID: 31982607
[TBL] [Abstract][Full Text] [Related]
11. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
Chang ML; Liaw YF; Hadziyannis SJ
Aliment Pharmacol Ther; 2015 Aug; 42(3):243-57. PubMed ID: 26151841
[TBL] [Abstract][Full Text] [Related]
12. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and meta-analysis.
Chen MB; Wang H; Zheng QH; Zheng XW; Fan JN; Ding YL; Yue MX
Medicine (Baltimore); 2019 Aug; 98(34):e16943. PubMed ID: 31441888
[TBL] [Abstract][Full Text] [Related]
14. Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies.
Liu YC; Jeng WJ; Peng CW; Chien RN; Liaw YF
Liver Int; 2022 Mar; 42(3):551-560. PubMed ID: 34936719
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B.
Behera MK; Pati GK; Narayan J; Mishra D; Meher LK; Singh A; Uthansingh K; Sahu MK
J Clin Exp Hepatol; 2021; 11(1):37-44. PubMed ID: 33679047
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang M; Qian M; Fu R; Zhang Y; Shen X; Yue D; Wang N; Yang L
Front Public Health; 2021; 9():709220. PubMed ID: 34568257
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.
Buti M; Wong DK; Gane E; Flisiak R; Manns M; Kaita K; Janssen HLA; Op den Brouw M; Jump B; Kitrinos K; Crans G; Flaherty J; Gaggar A; Marcellin P
Lancet Gastroenterol Hepatol; 2019 Apr; 4(4):296-304. PubMed ID: 30795958
[TBL] [Abstract][Full Text] [Related]
20. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift.
Liaw YF
Hepatol Int; 2019 Nov; 13(6):665-673. PubMed ID: 31559604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
